White Paper
Bariatric surgery is often seen as a turning point in a patient’s health journey, but weight loss alone doesn’t tell the full story. Beneath the surface, metabolic dysfunction and liver disease continue to influence long-term outcomes—often without consistent visibility or follow-up. In many cases, clinicians are still relying on assumptions rather than clear, trackable evidence.
In this white paper, bariatric surgeon Dr. Helmuth Billy shares how integrating noninvasive liver assessment with FibroScan® into bariatric care is changing how clinicians understand, monitor, and manage metabolic health. He outlines how these insights support more precise risk assessment, strengthen patient engagement, and enable a more proactive, longitudinal approach to care—both before and long after surgery.
MASLD is highly prevalent in bariatric populations, often progressing silently alongside obesity and increasing cardiovascular risk—making early detection and staging essential.
From Numbers to Real-World Change: Clear, trackable insights into liver health help patients better understand their condition—turning abstract risk into visible progress that can drive meaningful lifestyle change.
FibroScan® can be integrated into bariatric workflows with relative ease—supporting consistent utilization, strong reimbursement potential, and measurable value for both patients and practices.
Shared visibility into liver health supports collaboration across bariatric, hepatology, cardiology, and nutrition teams—enabling more coordinated and timely care.
Routine liver assessment reinforces accountability beyond surgery, helping patients stay engaged, monitor progress, and view metabolic health as an ongoing part of their care.
Bariatric surgeons are uniquely positioned to lead a more comprehensive approach to metabolic care—identifying, monitoring, and addressing liver disease as a key factor in long-term outcomes.